Sign in
Taking people in United StatesNo phase

Tests a stomach muscle cut procedure for weight loss in adults with obesity

Studies a stomach procedure, alone, for weight loss in adults with obesity.

Key facts

Who runs it
Christopher C. Thompson, MD, MSc
Where
Boston, United StatesSee the site
Trial code
Registry title
Efficacy and Safety of Endoscopic Antral Myotomy as a Novel Weight Loss Procedure
Status
Recruiting
People taking part
30 people, planned
Started
22 Sept 2023
Expected to end
Dec 2027
Type of study
Observational, 3 groups
Treatments tested
  • PSAM Treatment Patients
Record updated
2 March 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with a BMI above 35 kg/m2 who can have an endoscopic or surgical weight loss procedure. It tests a stomach muscle cut called PSAM for weight loss.

Age
18 to 70 years
Sex
All sexes can join.
Disease stage
Body mass index (BMI) greater than 35 kg/m2.
Earlier treatment
No opioid treatment in the 12 months before joining. No earlier pyloromyotomy or pyloroplasty. No earlier stomach or bowel surgery.

Main reasons for not taking part

  • Untreated H. pylori infection or gastroparesis
  • Active smoking
  • Pregnancy, puerperium or lactation
  • Inflammatory, malignant or premalignant disease of the stomach or gut
  • Severe heart or lung disease, or a history of coronary artery disease

The registry criteria, word for word

Show all 28 criteriaShow less

Who can take part

  • subjects must be 18-70 years of age
  • eligible for endoscopic and surgical weight loss procedures
  • body mass index (BMI) greater than 35 kg/m2
  • Individuals must be in excellent mental health
  • able to understand and sign informed consent
  • available to return for all routine follow-up study visits

Who cannot take part

  • an ongoing or a history of treatment with opioids in the last 12 months prior to enrollment
  • previous pyloromyotomy or pyloroplasty
  • use of any medication that may interfere with weight loss
  • use of any medication that may interfere with gastric emptying
  • untreated H. pylori infection
  • any inflammatory disease of the gastrointestinal tract (including but not limited to severe (LA Grade C or D) esophagitis, active gastric ulceration, active duodenal ulceration, or specific inflammation such as Crohn's disease)
  • malignant or premalignant gastric diseases (such as high grade dysplasia, gastric cancer, or GIST)
  • severe cardiopulmonary disease or a history of coronary artery disease (including myocardial infarction within the past 6 months, poorly controlled hypertension, required use of NSAIDs)
  • history of gastrointestinal surgery
  • any serious health condition unrelated to their weight that would increase the risk of endoscopy
  • a known history of endocrine disorders affecting weight (uncontrolled hypothyroidism)
  • any other condition which the investigator may deem as an impediment to compliance or hinder completion of the proposed study
  • gastroparesis
  • active smoking
  • gastrointestinal obstruction
  • severe coagulopathy
  • esophageal or gastric varices and/or portal hypertensive gastropathy
  • pregnancy or puerperium
  • lactation
  • chronic abdominal pain
  • active psychological issues preventing participation in a lifestyle modification program
  • an inability to provide informed consent

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 70 years old?

Where in United States

  • Brigham and Women's HospitalBoston, United StatesContact: Michele B. Ryan, MSTaking people

About the trial

What the trial wants to find out

Gastric myotomy has been performed for several years as a means of addressing chronic stenosis after sleeve gastrectomy and treating gastroparesis. The Pylorus Sparing Antral Myotomy (PSAM) technique has the opposite effect by leaving the pylorus intact and extending the myotomy proximally to the distal gastric body. PSAM was initially combined with ESG and shown to delay gastric emptying and provide greater weight loss without impacting tolerability (GCSI score) or the safety profile of the procedure (2 DDW GEM abstracts). PSAM has not been evaluated alone, without concomitant ESG. Since delayed gastric emptying alone is known to promote weight loss, it is thought that PSAM alone (without ESG) may provide similar efficacy, while reducing procedure time and adverse events. There have been no clinical studies that investigate the efficacy of PSAM independent of ESG. This pilot study aims to address this lack of information by evaluating the safety, tolerability, and short-term efficacy of PSAM, in addition to exploring its impact on gastric physiology. This will also provide data that may be used in designing a larger clinical trial.

The 3 groups in the trial

  • PSAM Treatment Patients with no prior endoscopic bariatric therapies

    Subjects with no prior endoscopic bariatric therapies having esophagogastroduodenoscopy (EGD) with Pylorus Sparing Antral Myotomy (PSAM) with standard of care lifestyle modification therapy.

    Treatment: PSAM Treatment Patients

  • PSAM Treatment Patients with prior primary endoscopic bariatric therapies

    Subjects with prior primary endoscopic bariatric therapies having esophagogastroduodenoscopy (EGD) with Pylorus Sparing Antral Myotomy (PSAM) with standard of care lifestyle modification therapy.

    Treatment: PSAM Treatment Patients

  • PSAM Treatment Patients with prior revision endoscopic bariatric therapies

    Subjects with prior revision endoscopic bariatric therapies having esophagogastroduodenoscopy (EGD) with Pylorus Sparing Antral Myotomy (PSAM) with standard of care lifestyle modification therapy.

    Treatment: PSAM Treatment Patients

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Efficacy and Safety of Endoscopic Antral Myotomy as a Novel Weight Loss Procedure: A Pilot Study
Plain-language title
Tests a stomach muscle cut procedure for weight loss in adults with obesityGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT05711758, who can take part
Record updated
2 March 2026